61.53
-0.75 (-1.20%)
| Previous Close | 62.28 |
| Open | 62.32 |
| Volume | 403,010 |
| Avg. Volume (3M) | 554,330 |
| Market Cap | 3,359,878,144 |
| Price / Earnings (Forward) | 15.67 |
| Price / Sales | 2.61 |
| Price / Book | 3.04 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Profit Margin | -17.42% |
| Operating Margin (TTM) | 15.54% |
| Diluted EPS (TTM) | -4.07 |
| Quarterly Revenue Growth (YOY) | 7.40% |
| Quarterly Earnings Growth (YOY) | 242.10% |
| Total Debt/Equity (MRQ) | 65.54% |
| Current Ratio (MRQ) | 1.58 |
| Operating Cash Flow (TTM) | 197.02 M |
| Levered Free Cash Flow (TTM) | 782.12 M |
| Return on Assets (TTM) | 4.55% |
| Return on Equity (TTM) | -19.70% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | LivaNova PLC | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -3.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 2.0 |
| Average | 0.38 |
|
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Core |
| % Held by Insiders | 0.38% |
| % Held by Institutions | 102.95% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 81.00 (Keybanc, 31.64%) | Buy |
| Median | 70.00 (13.77%) | |
| Low | 67.00 (Barclays, 8.89%) | Hold |
| Average | 72.00 (17.02%) | |
| Total | 4 Buy, 1 Hold | |
| Avg. Price @ Call | 62.03 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 09 Jan 2026 | 67.00 (8.89%) | Hold | 64.41 |
| Stifel | 07 Jan 2026 | 70.00 (13.77%) | Buy | 64.62 |
| Keybanc | 19 Dec 2025 | 81.00 (31.64%) | Buy | 62.82 |
| Mizuho | 17 Dec 2025 | 72.00 (17.02%) | Buy | 63.08 |
| 13 Nov 2025 | 70.00 (13.77%) | Buy | 55.20 | |
| Baird | 13 Nov 2025 | 70.00 (13.77%) | Buy | 55.20 |
| 06 Nov 2025 | 63.00 (2.39%) | Buy | 49.57 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 23 Dec 2025 | Announcement | LivaNova to Present at J.P. Morgan Healthcare Conference in January |
| 03 Dec 2025 | Announcement | LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting |
| 02 Dec 2025 | Announcement | LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea |
| 25 Nov 2025 | Announcement | LivaNova to Present at Piper Sandler Healthcare Conference in December |
| 24 Nov 2025 | Announcement | LivaNova’s VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services |
| 12 Nov 2025 | Announcement | LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day |
| 05 Nov 2025 | Announcement | LivaNova Reports Third-Quarter 2025 Results; Raises 2025 Guidance |
| 23 Oct 2025 | Announcement | LivaNova to Present at Wolfe Research Healthcare Conference in November |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |